Echosens is pleased to join other leading stakeholders in calling for increased vigilance and early detection of liver disease on World Liver Day, April 19, 2022. Chronic liver disease is a public health crisis that affects 1.9 billion people worldwide and accounts for two million1 deaths per year.
Chronic liver disease is largely the result of nonalcoholic fatty liver disease (NAFLD) and its more severe form nonalcoholic steatohepatitis (NASH), alcohol and viral hepatitis. Both NAFLD and NASH are close to becoming the number one reason for liver transplants in the United States.
While therapeutic treatments are in development, the best way to reduce the risk of advancing liver disease remains lifestyle modification – healthy eating and increased exercise. It’s also important to understand the impact of interventions and the increasingly beneficial role of FibroScan®, a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and liver fat at the point of care.
Benefits of FibroScan®
Typically, NAFLD is asymptomatic, making point-of-care examinations, monitoring and ongoing assessment of liver fat and stiffness as provided by FibroScan® a more cost-effective way to identify individuals who are asymptomatic and undiagnosed for liver damage. It can also provide metrics for monitoring changes in liver fat due to lifestyle modification.
World Liver Day is an excellent time to get involved, share information about liver health and diseases, as well as the growing need for rapid screening and monitoring of liver stiffness and fat at the point of care.
1.Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151-171. doi: 10.1016/j.jhep.2018.09.014. Epub 2018 Sep 26. PMID: 30266282.